Distinguished in Large-Cell Immunoblastic Lymphoma

Dr. Jonathan S. Treisman

Hematology Oncology | Oncology | Hematology
Ascension Medical Group-Southeast Wisconsin Inc
7410 W Rawson Ave, 
Franklin, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Distinguished in Large-Cell Immunoblastic Lymphoma
Ascension Medical Group-Southeast Wisconsin Inc
7410 W Rawson Ave, 
Franklin, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jonathan Treisman is a Hematologist Oncology specialist and an Oncologist in Franklin, Wisconsin. Dr. Treisman is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. His top areas of expertise are Colorectal Cancer, Lynch Syndrome, Familial Colorectal Cancer, Large-Cell Immunoblastic Lymphoma, and Bone Marrow Aspiration. Dr. Treisman is currently accepting new patients.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in WI
Hospital Affiliations
Aurora St Lukes Medical Center
Ascension All Saints Hospital
Ascension Se Wisconsin Hospital
Ascension St Francis Hospital
Ascension Columbia St Mary's Hospital Milwaukee
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Common Ground Healthcare Cooperative
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Icare Independent Care Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

ASCENSION MEDICAL GROUP-SOUTHEAST WISCONSIN INC
7410 W Rawson Ave, Franklin, WI 53132

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Integrated Cancer Repository for Cancer Research
Integrated Cancer Repository for Cancer Research
Enrollment Status: Recruiting
Publish Date: June 10, 2025
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Other
Study Drug: Pazopanib Hydrochloride
Study Phase: Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR)
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Other, Procedure
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
View 17 Less Clinical Trials

9 Total Publications

Brief Report on Use of Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis.
Brief Report on Use of Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis.
Journal: Clinical lung cancer
Published: November 08, 2022
Similar Doctors
Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Sayed H. Hamadani
Hematology Oncology | Hematology | Oncology
Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Sayed H. Hamadani
Hematology Oncology | Hematology | Oncology

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
 (8.9 miles away)
414-805-3666
Languages Spoken:
English, Punjabi, Urdu
See accepted insurances
Accepting New Patients

Sayed Hamadani is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Hamadani is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Hamadani is currently accepting new patients.

Nirav N. Shah
Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Nirav N. Shah
Hematology Oncology | Hematology | Oncology
Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Nirav N. Shah
Hematology Oncology | Hematology | Oncology

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
 (8.9 miles away)
414-805-3666
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nirav Shah is a Hematologist Oncology specialist and a Hematologist in Milwaukee, Wisconsin. Dr. Shah is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. His top areas of expertise are Marginal Zone Lymphoma (MZL), Large-Cell Immunoblastic Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Shah is currently accepting new patients.

Dean G. Tsarwhas
Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Dean G. Tsarwhas
Hematology | Oncology
Distinguished in Large-Cell Immunoblastic Lymphoma
Dr. Dean G. Tsarwhas
Hematology | Oncology
1000 N Westmoreland Rd Level 1, Pavilion A, 
Lake Forest, IL 
 (47.5 miles away)
847-582-2134
Experience:
38+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dean Tsarwhas is a Hematologist and an Oncologist in Lake Forest, Illinois. Dr. Tsarwhas has been practicing medicine for over 38 years and is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Immunoblastic Lymphoma. His top areas of expertise are Sezary Syndrome, Paget Disease of the Breast, Angiosarcoma, and Large-Cell Immunoblastic Lymphoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Treisman's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 35 Advanced Conditions
    View All 160 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile